Press Release: Oxford Immunotec : PerkinElmer's Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer's (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories. The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs. The increased use of automation also improves blood